Genprex announces advancement of diabetes program, strategic collaboration

Genprex (GNPX) announced the advancement of its diabetes program through a strategic collaboration with a contract development and manufacturing organization to research an alternative second generation approach using a non-viral lipid nanoparticle delivery of the Company’s diabetes gene therapy drug candidate. “This collaboration with our CDMO partner is separate from our existing preclinical research programs and seeks to evaluate potential next generation construct optimization,” said Ryan Confer, President and Chief Executive Officer at Genprex. “This exploratory research represents our forward-thinking approach within our diabetes program to determine if our novel diabetes gene therapy could be delivered using a non-viral delivery system, similar to Genprex’s oncology drug candidate. While AAV delivery is a well understood delivery mechanism, there are many benefits to a non-viral delivery system, including the potential for re-dosing patients to optimize treatment. This collaboration positions Genprex as a thought-leader in gene therapy, specifically within the diabetes market where there are only symptom managing therapies but no disease modifying technologies.”